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Abstract
Manifestations of Legionella infections range from benign, mild disease to a 
more severe form with increased morbidity and mortality, especially in untreated 
patients. Despite diagnostic advances, clinical diagnosis remains elusive. Macrolides 
and respiratory fluoroquinolones remain the antibiotics of choice for treatment of 
Legionella; however, several new antibiotics are currently under development or 
in clinical trials. The recommended duration of antibiotics is 5–7 days; although, 
some critically ill or immunosuppressed patients may require longer treatment. In 
vivo resistance to these antibiotics is rare, and there is no evidence that combination 
therapy is more beneficial than monotherapy. Early suspicion, diagnosis, and treat-
ment are paramount for improving outcomes.
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1. Introduction
Initial recognition of Legionnaires’ disease dates back to 1976 during an out-
break of respiratory illness in Philadelphia, PA at an American Legion convention 
[1]. The Legionellaceae family is extensive and contains more than 40 species, but 
less than half produce disease in humans, with Legionella pneumophila being the 
most common [2]. Legionella infections usually manifest in two forms. The most 
benign presentation is Pontiac fever, which typically presents as an acute, febrile, 
upper respiratory tract infection (non-pneumonic) that is often unrecognized and 
resolves spontaneously [3]. The most severe presentation is Legionnaires’ disease, 
caused by Legionella pneumophila. It is an atypical pneumonia, generally affect-
ing the lungs and gastrointestinal tract [4]. The disease affects people of all ages 
and causes significant morbidity and mortality, especially in patients with certain 
comorbid conditions. An estimated 10,000–18,000 people worldwide are infected 
with Legionella each year [5].
In a recent review, most Legionella pneumonia cases were reported in the 
Northern hemisphere. Common workplaces associated with this infection were 
industrial settings, office buildings, and healthcare facilities [6]. Legionella pneu-
monia was associated with mortality in 4.1% of all cases.
The clinical and radiological manifestations of Legionella are nonspecific. As 
a result, if suspected, empiric antibiotics treatment is recommended to improve 
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morbidity and mortality associated with the disease [7, 8]. The goal of this review 
is to provide a concise discussion regarding indications for treatment of Legionella, 
update the information about antibiotic management, and discuss outcomes of the 
disease.
2. Pathogenesis
Legionella are aerobic, Gram-negative, facultative, intracellular bacilli found 
widely in the environment; they have been isolated from many water sources and 
often colonize manufactured water systems. Humans are infected by exposure to 
water contaminated with Legionella. Person-to-person transmission has been dem-
onstrated in only one case thus far and is not considered to be a primary means of 
transmission. Thus, the human body may be considered a “dead-end” for Legionella. 
Legionella can cause sporadic and potentially life-threatening infections in immuno-
compromised individuals, especially the young and elderly.
Infection begins when humans inhale Legionella, which travels to the lower 
respiratory tract where the organism binds to alveolar macrophages and engulfed 
into the phagosomal vacuoles (also known as phagosomes). Legionella then 
blocks fusion of the phagosome with lysosomes, preventing the release of lyso-
somal enzymes that destroy bacterial cells. Consequently, the bacteria can freely 
divide in the phagosome. Eventually, the cell ruptures, releasing bacteria that 
can infect other cells, resulting in inflammation and sepsis. Given the lifecycle 
of Legionella, an effective antibiotic requires both anti-Legionella activity and a 
high intracellular minimum inhibitory concentration in alveolar macrophages 
[9]. Antibiotics that have demonstrated clinical effectiveness in Legionnaires’ 
disease include macrolides, fluoroquinolones, tetracyclines, trimethoprim-
sulfamethoxazole (TMP-SMX), and rifampin [9]. We describe the details of each 
of these antibiotics below.
3. Treatment
3.1 Macrolides
Bacterial ribosomes have two subunits (30S and 50S) that function in protein 
synthesis. In contrast, the ribosomes in animal cells have 40S and 60S subunits, and 
this difference ensures that different classes of antibiotics are active against bacteria 
and not human cells. Macrolides are bacteriostatic agents that bind reversibly to the 
50S ribosomal subunit and inhibit protein synthesis [10]. They are active against 
a wide range of bacteria, including intracellular pathogens such as Legionella. 
Macrolides, especially azithromycin, reach peak concentration in 2–3 hours and are 
rapidly absorbed and distributed throughout body tissues and with good cell dis-
tribution [10]. In the past, macrolides, especially erythromycin, have been the drug 
of choice for treatment of Legionnaires’ disease. A newer derivative, azithromycin, 
recently surpassed erythromycin, because azithromycin has fewer side effects 
and fewer interactions with other drugs than erythromycin or its counterpart, 
clarithromycin.
Despite macrolides’ effectiveness, bacteria have developed multiple resistance 
mechanisms to these drugs. One mechanism is an active efflux pump to pump the 
drug out of the cell. Another resistance mechanism involves changing the ribo-
somal subunit, either by inducing genes to produce a methylase enzyme (ermA, 
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ermB, and ermC) that modifies the ribosome target or by causing chromosomal 
mutation of the 50S ribosomal subunit. Changes in the ribosomal subunit struc-
ture decrease drug binding to the ribosome and result in decreased efficacy of the 
drug [10].
Common side effects of macrolides include gastrointestinal disturbances like 
dyspepsia, anorexia, flatulence, and arthralgias, and disturbance in taste and smell. 
Rarely, hepatitis, hepatic failure, thrombocytopenia, interstitial nephritis, photo-
sensitivity, and renal failure are observed [10]. A prolonged QTc is more common 
with older macrolides, such as erythromycin and clarithromycin. Azithromycin, 
even is taken with antacids, appears to be free of drug interactions.” Caution is 
advised, nevertheless, when using azithromycin in conjunction with drugs known 
to interact with erythromycin [10].
3.2 Fluoroquinolones
Along with macrolides, fluoroquinolones (levofloxacin, moxifloxacin, and 
ciprofloxacin) have increasingly become a drug of choice against Legionella. These 
drugs have broad-spectrum activity against Gram-positive and Gram-negative 
organisms, such as Legionella [11]. Fluoroquinolones inhibit DNA gyrase subunit 
A, a bacterial enzyme that relieves the tension produced when DNA unwinds 
during replication. Binding to DNA gyrase inhibits the transcription of bacterial 
DNA, resulting in bacterial cell death. Levofloxacin has an advantage in treating 
pneumonia, as this drug has two to five times higher concentrations in lung tissue 
than in serum. Bioavailability for levofloxacin is 99% for oral and intravenous (IV) 
medications [11]. Fluoroquinolones exhibit concentration-dependent antimicrobial 
activity [12].
Bacterial resistance to quinolones mostly occurs by chromosomal mutations to 
the DNA gyrase gene, resulting in reduced affinity of the drug to the enzyme. Also, 
similar to macrolides, alterations in drug efflux or cell membrane porin channels 
can occur, decreasing the intracellular concentration of drug [11].
Side effects of fluoroquinolones include benign rash, headaches, nausea, vomit-
ing, diarrhea, prolonged QTc, and arrhythmia. Tendonitis and tendon rupture have 
been reported in young and elderly patients. Fluoroquinolones can also cause liver 
dysfunction. Many over-the-counter (e.g., iron, calcium, zinc, and non-steroidal 
anti-inflammatory drugs) and prescription medications (e.g., warfarin) can inter-
act with levofloxacin [13].
3.3 Tetracyclines
Tetracyclines are a class of antibiotics that include doxycycline, minocycline, 
tetracycline, and tigecycline. These drugs are reversible competitive inhibitors and 
inhibit protein synthesis at the level of the ribosome via inhibition of the codon-
anticodon interaction between tRNA and mRNA. These antibiotics block binding 
of tRNA to the 30S ribosomal subunit, thus preventing the addition of new amino 
acids for protein building. Because this process is reversible, these drugs are bacte-
riostatic [14].
Resistance to tetracyclines is acquired via bacterial conjugation, where plasmids 
or transposons containing resistance genes are transferred to the previously sensi-
tive bacteria. The resistance genes produce modified bacterial porins, preventing 
uptake of the tetracyclines into the bacterial cell. Other mechanisms of resistance 
include increased drug efflux, decreased ribosomal binding, and enzymatic inacti-
vation [14].
Legionnaires Disease
4
Tetracyclines can cause many adverse effects, including several that are life-
threatening. Tetracyclines concentrate in growing teeth and bones and thus should 
be avoided by children and pregnant patients [14]. Additionally, tetracyclines 
can cause nephrotoxicity and hepatotoxicity due to fatty degeneration. Pregnant 
women are at increased risk of hepatotoxicity, and tetracyclines can potentiate the 
nephrotoxic effects of aminoglycosides and other nephrotoxic drugs. Furthermore, 
tetracyclines can induce photosensitivity in persons exposed to the sun during 
treatment [14].
3.4 Trimethoprim-sulfamethoxazole
TMP-SMX is one of the most widely used antibiotics in the world. 
Sulfonamides such as SMX are competitive inhibitors of para-aminobenzoic 
acid, and TMP inhibits dihydrofolate reductase to block the formation of tetra-
hydrofolate, a key cofactor in the construction of purine, thymidine, DNA, and 
amino acids [15]. Bacterial dihydrofolate reductase is inhibited 50–60,000 times 
more than mammalian enzymes; thus, this antibiotic has minimal effect on 
human cells [15]. Both sulfonamides and TMP act synergistically and have 
maximal activity when the concentration of SMX is 20 times greater than that 
of TMP.
Although well tolerated, TMP-SMX can cause many gastrointestinal side effects, 
including nausea, vomiting, and anorexia as well as rash. Sulfonamides can cause 
skin rashes, including hypersensitivity reactions that can progress from a mild 
reaction to erythema multiforme as Stevens-Johnson syndrome. Rarely, TMP-SMX 
can cause aplastic anemia, agranulocytosis, and fulminant hepatic necrosis [15]. 
Sulfonamides can cause hemolytic anemia in patients with glucose-6-phosphate 
dehydrogenase deficiency.
3.5 Rifampin
Rifampin is also effective against Legionella, as this drug inhibits bacterial and 
mycobacterial RNA synthesis by binding to the beta subunit of DNA-dependent RNA 
polymerase to prevent RNA transcription [16]. Rifampin is absorbed readily and 
has good penetration into the lungs and pleural fluid. Depending on concentrations 
reached in the infected cell and the susceptibility of the organism, rifampin can exert 
either bactericidal or bacteriostatic effects [16]. Most bacteria develop resistance to 
rifampin as the result of a gene mutation in the beta subunit of DNA-dependent RNA 
polymerase. Rifampin therapy is recommended only for patients with severe disease 
or significant comorbid conditions (e.g., poorly controlled diabetes, tobacco use, or 
obstructive lung disease) including immunocompromised hosts and those refractory 
to conventional monotherapy regimens. Significant adverse drug events and drug-
drug interactions should be considered with the use of rifampin.
Rifampin should not be used as monotherapy but rather can provide a signifi-
cant synergistic effect when used in combination with other antibiotics such as 
macrolides or quinolones [17].
Oral and IV dosing is equivalent. Rifampin induces many hepatic CYP450 
isoenzymes and can enhance the metabolism of endogenous substrates, including 
adrenal hormones, thyroid hormones, and vitamin D. Other side effects include 
maculopapular rash, fever, nausea, and vomiting. Furthermore, this antibiotic 
can cause Clostridium difficile colitis, hepatitis, and liver toxicity and can result 
in yellow, red, or orange discoloration of bodily fluids. Soft contact lenses may be 
permanently stained. Rifampin can also cause postnatal hemorrhages in the mother 
and infant [16] (Table 1).
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3.6 Drug dosing and duration
A summary of the most common antibiotics used with doses and duration can 
be seen below in Table 1.
3.7 Macrolides compared with fluoroquinolones
Previous studies have shown that patients treated with older macrolides have 
a higher recurrence of disease after antibiotics are withdrawn. Levofloxacin and 
azithromycin appear to be the ideal drugs against Legionella because re-growth is not 
observed. In fact, numerous societies, including Infectious Diseases Society of America, 
British Thoracic Society, and the Dutch Association of Chest Physicians, recommend 
fluoroquinolones or azithromycin as the preferred antimicrobial therapy for Legionella 
[18]. Comparison of levofloxacin with azithromycin in the treatment of Legionella has 
shown no difference between the two antibiotics regarding time to defervescence, time 
to achieve clinical stability, length of IV therapy, or length of hospital stay [12].
Other antibiotics potentially effective for Legionella include tigecycline. A small 
study in eight patients with Legionella suggest tigecycline as potential second-line 
agent for treatment of patients with severe Legionnaire’s responding poorly to 
conventional first line agents such as levofloxacin and azithromycin [19].
4. Outcomes
A majority of patients with Legionella pneumonia have favorable outcomes. 
Mortality ranges from 1.8 to 10%. Mortality is higher in patients with sporadic 
infections compared to outbreak-related cases [20, 21]. Mortality is also higher in 
patients with hospital-acquired legionellosis, transplant recipients with unusual 
presentations, and missed diagnosis with negative urinary antigen [22, 23]. ICU 
admissions vary based on severity and underlying conditions, especially immuno-
compromised status.
Clinical features of Legionella infection in immunocompromised patients 
include infection (most commonly presenting as pneumonia), cavity, and empy-
ema. Extrapulmonary disease can be present, and the urine antigen test is less 
Antibiotic Administration Dose Frequency Duration (days)
Ciprofloxacin IV 200–400 mg Every 12 hours 10
or
Oral 500 mg Every 12 hours 10
Levofloxacin IV or oral 500 mg Daily 7–14
Moxifloxacin IV or oral 400 mg Daily 14
Azithromycin IV or oral 500 mg Daily 7–10
Erythromycin IV 1 g Every 6 hours 10–14
Doxycycline* IV or oral 200 mg Twice a day 3
IV or oral 100 mg Twice a day 11
*Doxycycline administered 200 mg 2×/day for 3 days followed by 100 mg 2×/day for 11 days.
Table 1. 
Recommended drug dosing and duration for antibiotics effective against Legionella.
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sensitive [24]. There are no differences in mortality rates, length of hospital stay, 
development of C. difficile infection, or hospital costs based on chosen therapy 
(fluoroquinolones versus azithromycin) [25].
4.1 Legionella pneumonia and extracorporeal membrane oxygenation (ECMO)
Patients with Legionella pneumonia with severe acute respiratory distress 
syndrome can be treated with ECMO. Several case reports describe the outcomes 
of patients with Legionella pneumonia requiring ECMO [26–28]. With respect to 
outcomes for refractory respiratory failure in patients with Legionella pneumonia, 
Roncon et al. reported that 14 of 112 patients treated with ECMO had Legionella 
pneumonia [29]. Legionella pneumonia was associated with earlier ECMO initia-
tion, higher static compliance and a non significant trend towards hospital survival.
4.2 HIV infection and Legionella pneumonia
Legionella pneumonia in HIV-infected patients is uncommon; however, some 
studies suggest that it occurs 40 times more frequently in patients with AIDS than 
in the general population [30–32]. There are also conflicting reports on the severity 
and outcomes of HIV infection and Legionella pneumonia [33]. A recent review 
reported that the incidence of Legionella pneumonia occurs in 6% of bacterial 
pneumonias in HIV infected patients [34]. .Some reasons for a lower incidence in 
AIDS patients include a possible protective role of Pneumocystis jirovecii pneumonia 
(PJP) prophylaxis with TMP-SMX or the failure to isolate or diagnose Legionella 
as a coinfection. A recent study revealed that Legionella could be found in the 
bronchoalveolar fluid in AIDS patients presenting with tuberculosis and PJP [35]. 
This study also revealed that species-specific coinfection could occur, associating L. 
pneumophila with M. tuberculosis and other Legionella species with P. jirovecii.
Although most of the data on Legionella pneumonia in HIV patients are from 
case reports, a recent case-matched, case-control study reported that HIV patients 
presenting with community-acquired Legionella pneumonia have similar outcomes 
compared to non-HIV patients. HIV infection is not associated with higher ICU 
admission or increased length of hospital stay in these patients [36], and the dura-
tion of therapy is similar to non-HIV patients.
4.3 Pregnancy and Legionella pneumonia
The estimated prevalence of antepartum pneumonia is similar to that for the 
non-pregnant population at 0.78–2.7 per 1000 [37]. Although Streptococcus pneu-
moniae is the most common responsible pathogen, Legionella has also been reported 
[38, 39]. Legionella was implicated as a causative agent in 1.2% of pneumonias in 
pregnancy [40]. Treatment is similar to that of non-pregnant women. Worse out-
comes have not been described, and fetal demise rarely occurs [38, 39, 41]. Factors 
associated with favorable outcomes include a high index of suspicion, the institu-
tion of appropriate early therapy, and presentation in the late third trimester [38].
5. Conclusions
Appropriate and timely administration of antibiotics in patients suspected 
with Legionella infection is highly recommended. Macrolides and fluoroquinolones 
are considered the drugs of choice for treatment. In critically ill patients or those 
patients not responding appropriately, combination therapy should be considered 
7Advances in Treatment and Outcomes of Patients with Legionella Infection
DOI: http://dx.doi.org/10.5772/intechopen.88481
with careful evaluation of side effects and drug interactions. As for other infec-
tions, outcomes are not only related to the choice of antibiotics but also specific host 
factors and aggressive supportive measures. Furthermore, it is important to review 
antibiotic resistance patterns not only in clinical patients but also in environmental 
strains that are a potential source of the clinical infections [18].
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